Problems in the Health Care Sector
The private and public health care sector is turning to improved technological solutions to reduce the incidence of Clostridium difficile (C difficile) and MRSA (Methicillin-resistant Staphylococcus Aureus). C difficile and MRSA are a major cause of antibiotic-associated diarrhea, colitis, and other infections that can be both debilitating and sometimes lethal. In a recent study, it was found that 31% of patients who received antibiotics in acute care medical wards were colonized with C difficile, and 56% of these patients developed C difficile associated diarrhea.

Use of Standard Cleaners
The present technology used by the health care industry employs a manual cleaning process in conjunction with disinfecting liquids such as accelerated H₂O₂. This consists of a physical cleaning H₂O₂ process that is labour intensive, low-tech and often unreliable because it is not uniform in its application. The increasing frequency of infectious disease outbreaks requires a new and innovative solution to the problem.

The Solution: ViroForce 1000
Research studies have shown that ViroForce 1000 can kill 99.99% of all C difficile and MRSA in a treated space. Since it is a gas, it sanitizes hard and soft surfaces and inaccessible areas. It is therefore the perfect solution for use in sanitizing hospital patient, examination and operating rooms. It is also ideal for use in doctors' offices and medical clinics, as well as long-term health care facilities.

ViroForce 1000 is a mobile automated disinfecting device using ozone gas made from ambient air. It has a 30 minute turnaround time per average-sized room. After treatment, the space is 99.99% sanitized from viruses and bacteria and can be safely re-occupied with no adverse effects on materials or occupants.

Costs to Hospitals
The trend in the health care system is to reduce costs and increase efficiencies, as well as improve the quality of service demanded by patients. The cost of these diseases to hospitals in North America and the United Kingdom is more than US$21B per annum. If the ViroForce technology is implemented in one hospital, the anticipated savings to the average hospital would be over US$2.3 million per annum*.

*See Computer Simulation Study on the Effects of Ozone Treatment on the Cost of a Norovirus Outbreak in a Simple Hospital Ward
Dr. Nobel’s Ozone in Hospital Norovirus Outbreak.pdf  

Country	No. of Hospitals.	Annual Cost US$
United States	5,200	$ 12.37 B
Canada	1,200	$   2.80 B
United Kingdom	2,500	$   5.95 B
TOTAL  COST		$ 21.12 B